Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Bangkok Post - November 23, 2004
Apiradee Treerutkuarkul
Tongchai Thavichachart, director of the Government Pharmaceutical Organisation (GPO), said yesterday the state enterprise under the Public Health Ministry was in the process of registering the formula of GPO-VIR S-30, a low-cost Aids treatment pill, with the US Food and Drug Administration (USFDA), so that it could produce the drug for export on a par with the USFDA standards.
The GPO would also send a team of officials to discuss the matter with the USFDA on Dec 7, he said.
At the International Aids Conference held in Bangkok in mid-July, the US administration stated its intention to buy low-cost anti-retroviral pills from Thailand for patients in developing countries under the PEPFAR programme.
Public Health Minister Sudarat Keyuraphan said she hoped the US agency would quickly approve the Thai proposal.
She said her ministry would speed up the opening of a new state pharmaceutical factory to increase GPO-VIR production capacity so as to meet an expected rise in demand once the US gives the Thai medicine its stamp of approval.
"It is good news for Thailand that our anti-Aids drugs will contribute huge benefits for HIV-positive people in the global community as soon as the US government approves the medical standard for GPO-VIR," the minister said.
Washington has launched a US$15 billion (600 billion baht) fund for PEPFAR to help curb HIV infection and assist people living with HIV/Aids in 14 afflicted countries in Africa, the Carribean and Vietnam.
However, Samlee Jaidee, an adviser to the Drug Study Group, questioned the Thai and US governments' actions on the distribution of Aids drugs when only around 50,000 out of the 120,000 people living with HIV/Aids in Thailand had access to anti-retroviral treatment.
She also said the US government was being hypocritical in seeking low-cost drugs for HIV-positive people in developing countries.
It should instead be providing them with brand-name drugs produced by US-based pharmaceutical companies.
041123
BP041105
Copyright © 2004 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .